Affiliation:
1. Department of Surgery Sheba Medical Center, Tel Hashomer Affiliated to the Tel‐Aviv University Tel‐Aviv Israel
2. Section of Hematology/Oncology Department of Medicine University of Chicago Medical Center Chicago Illinois USA
3. Section of Surgical Oncology Department of Surgery University of Chicago Medical Center Chicago Illinois USA
4. Department of Pathology University of Chicago Medical Center Chicago Illinois USA
5. Division of Surgical Oncology Department of Surgery University of California Irvine Orange California USA
6. Division of Hematology, Medical Oncology and Palliative Care Department of Medicine University of Wisconsin Madison Wisconsin USA
Abstract
AbstractBackgroundThis study aimed to investigate if peritoneal mesothelioma (PM) patients with germline mutations (GM) have distinct surgical characteristics when compared to those without GM.MethodsPM patients were selected from an ongoing prospective study that conducts germline testing of 82 susceptibility genes. Germline status was correlated with surgical data obtained from a prospectively collected database using univariate, multivariate, and receiver operating characteristic (ROC) analyses.ResultsOut of 88 PM patients enrolled between 2009 and 2019, 18 GMs (20.5%) were identified in BRCA1‐associated protein 1 (BAP1) (n = 11, 12.5% of all patients), SDHA (n = 2) and WT1, CDKN2A, CHEK2, ATM, and BRCA2 (n = 1 patient each). Surgical procedures were performed in 71 patients, the most common of which were cytoreductive surgeries with hyperthermic intraperitoneal chemotherapy (n = 61). Patients with GM presented with a higher prevalence of other prior cancers (61.1% vs. 31.4%, p = .02) and lower platelet count (251 [160–413] vs. 367 [196–780] K/µL, p = .005) compared to those without GM (n = 70). Survival outcomes did not differ significantly between the groups. Patients with BAP1 GMs were more likely to develop bicavitary disease and to present with lower platelet count and mitotic count score, and higher peritoneal cancer index (PCI, all p ≤ .04) compared with those without GM. On ROC analysis, the combination of PCI, platelet count and mitotic score yielded an area under the curve of 0.96 (95% CI, 0.91–1.0) for BAP1 GM detection among operated PM patients.ConclusionHigher intraoperative tumor burden and lower platelet count and mitotic score are suggestive of BAP1 GMs in surgical PM patients and should prompt germline testing.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献